Identifying SOX17 as a Sensitive and Specific Marker for Ovarian and Endometrial Carcinomas

• Published in: Modern pathology Vol. 36; no. 1; p. 100038
• Main Authors: Shaker, Nada, Chen, Wei, Sinclair, William, Parwani, Anil V, Li, Zaibo
• Format: Journal Article
• Language: English
• Published: United States 01-01-2023
• Subjects: Adenocarcinoma, Mucinous; Biomarkers, Tumor - metabolism; Endometrial Neoplasms - diagnosis; Endothelial Cells - pathology; Female; Genital Neoplasms, Female - pathology; Hemangiosarcoma; Humans; Immunohistochemistry; Ovarian Neoplasms - pathology; Paired Box Transcription Factors; PAX8 Transcription Factor; SOXF Transcription Factors - genetics; gynecologic tumors; PAX8; SOX17; biomarker; nongynecologic tumors
• ISSN: 0893-3952; 1530-0285
• DOI: 10.1016/j.modpat.2022.100038

Similar to PAX8, SOX17 was recently identified as a master transcription factor of ovarian cancer based on RNA sequencing data. We explored SOX17 utility in diagnosing ovarian tumors and other gynecologic tumors. We systematically evaluated SOX17 expression on tissue microarrays of 398 ovarian tumors of various types, 93 endometrial carcinomas, 80 cervical carcinomas, and 1371 nongynecologic carcinomas, such as those of kidney, thyroid, breast, colon, bladder, liver, bile duct, adrenal gland, pancreas, brain, and lung and malignant melanoma. In addition, we evaluated SOX17 expression in whole tissue sections from 60 gynecologic carcinomas and 10 angiosarcomas. The results demonstrated that SOX17 was highly expressed in most ovarian and endometrial tumors with strong intensity. However, unlike PAX8, it was predominately negative in other tested tumor types, including kidney and thyroid tumors. In particular, SOX17 was highly expressed in the following pathologic subtypes of ovarian tumors: serous carcinoma, clear cell carcinoma, endometrioid carcinoma, and germ cell tumors. SOX17 was mostly negative in mucinous carcinoma and sex cord stromal tumors. In addition, SOX17 was expressed in vascular endothelial cells and was positive in all tested angiosarcomas. In summary, our results demonstrate that SOX17 is a sensitive and specific marker for ovarian nonmucinous carcinomas and endometrial carcinomas. For ovarian germ cell tumors and angiosarcomas, SOX17 demonstrates higher specificity than PAX8, with comparable sensitivity. Furthermore, SOX17 positivity in endothelial cells serves as an internal positive control, making it an excellent marker.